

Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (the “**Hong Kong Stock Exchange**”) and Hong Kong Securities Clearing Company Limited (“**HKSCC**”) take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Unless otherwise defined in this announcement, capitalized terms used herein shall have the same meanings as those defined in the prospectus dated March 20, 2026 (the “**Prospectus**”) issued by Hangzhou Diagens Biotechnology Co., Ltd. (杭州德適生物科技股份有限公司) (the “**Company**”).

This announcement is for information purposes only and does not constitute an offer or an invitation to induce an offer by any person to acquire, purchase or subscribe for any of the securities of the Company. This announcement is not a prospectus. Potential investors should read the Prospectus for detailed information about the Global Offering described below before deciding whether or not to invest in the Offer Shares. Any investment decision in relation to the Offer Shares should be taken solely in reliance on the information provided in the Prospectus.

This announcement does not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of Offer Shares in any jurisdiction in which such offer, solicitation or sales would be unlawful. This announcement is not for release, publication or distribution, directly or indirectly, in or into the United States or any other jurisdiction where such distribution is prohibited by law, nor is this announcement an offer for sale or solicitation to purchase or subscribe for securities in the United States or any other jurisdictions. The Offer Shares have not been, and will not be, registered under the United States Securities Act of 1933, as amended from time to time (the “**U.S. Securities Act**”), or any applicable state securities laws, and may not be offered, sold, pledged or transferred within the United States or to, or for the account or benefit of, U.S. persons (as defined in Regulation S under the U.S. Securities Act (the “**Regulation S**”)) except in transactions exempt from, or not subject to, the registration requirements of the U.S. Securities Act. The Offer Shares are being offered and sold outside the United States in offshore transactions in accordance with Regulation S. There will be no public offering of the Offer Shares in the United States.

No stabilizing manager will be appointed, and it is anticipated that no stabilization activities will be carried out in relation to the Global Offering.

The Hong Kong Offer Shares will be offered to the public in Hong Kong subject to the terms and conditions set out in the Prospectus. The Hong Kong Offer Shares will not be offered to any person who is outside Hong Kong and/or not resident in Hong Kong. Potential investors of the Offer Shares should note that the Sponsor-overall Coordinator (for itself and on behalf of the Hong Kong Underwriters) shall be entitled to terminate its obligations under the Hong Kong Underwriting Agreement with immediate effect upon the occurrence of any of the events set out in the paragraph headed “Underwriting – Underwriting Arrangements and Expenses – Hong Kong Public Offering – Grounds for Termination” in the Prospectus at any time prior to 8:00 a.m. (Hong Kong time) on the Listing Date (which is currently expected to be on Monday, March 30, 2026).



Hangzhou Diagens Biotechnology Co., Ltd.

杭州德適生物科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

Global Offering

Number of Offer Shares under : 7,999,200 H Shares
the Global Offering
Number of Hong Kong Offer Shares : 799,950 H Shares
Number of International Offer Shares : 7,199,250 H Shares
Final Offer Price : HK\$99.0 per H Share, plus brokerage of
1.0%, SFC transaction levy of 0.0027%,
AFRC transaction levy of 0.00015% and
Hong Kong Stock Exchange trading fee of
0.00565%
Nominal value : RMB1.00 per H Share
Stock code : 2526

***Sole Sponsor, Sponsor-overall Coordinator, Overall Coordinator,
Joint Global Coordinator, Joint Bookrunner and Joint Lead Manager***



***Overall Coordinator, Joint Global Coordinator,
Joint Bookrunner and Joint Lead Manager***



Joint Bookrunners and Joint Lead Managers



Hangzhou Diagens Biotechnology Co., Ltd.

杭州德適生物科技股份有限公司

ANNOUNCEMENT OF FINAL OFFER PRICE AND ALLOTMENT RESULTS

Unless otherwise defined herein, capitalized terms used in this announcement shall have the same meanings as those defined in the prospectus dated March 20, 2026 (the “**Prospectus**”) issued by Hangzhou Diagens Biotechnology Co., Ltd. (杭州德適生物科技股份有限公司) (the “**Company**”).

SUMMARY

Warning: In view of high concentration of shareholding in a small number of H Shareholders, H Shareholders and prospective investors should be aware that the price of the H Shares could move substantially even with a small number of H Shares traded and should exercise extreme caution when dealing in the H Shares.

Company information

Stock code	2526
Stock short name	DIAGENS-B
Dealings commencement date	March 30, 2026*

* see note at the end of the announcement

Price Information

Final Offer Price	HK\$99.0
Offer Price Range	HK\$95.6 - HK\$112.5
Offer Price Adjustment exercised	N/A

Offer Shares and Share Capital

Number of Offer Shares	7,999,200
Number of Offer Shares in the Hong Kong Public Offering	799,950
Number of Offer Shares in the International Offering	7,199,250
Number of issued shares upon Listing	88,879,200

Proceeds	
Gross proceeds ^{Note}	HK\$791.9 million
Less: Estimated listing expenses payable based on Final Offer Price	HK\$72.11 million
Net proceeds	HK\$719.8 million

Note: Gross proceeds refers to the amount to which the issuer is entitled receive. For details of the use of proceeds, please refer to the section headed “Future Plans and Use of Proceeds” of the Prospectus.

ALLOTMENT RESULTS DETAILS

HONG KONG PUBLIC OFFERING

No. of valid applications	115,017
No. of successful applications	14,278
Subscription level	1,073.37 times
Reallocation	No
No. of Offer Shares initially available under the Hong Kong Public Offering	799,950
No. of Offer Shares reallocated from the International Offering	0
Final no. of Offer Shares under the Hong Kong Public Offering	799,950
% of Offer Shares under the Hong Kong Public Offering to the Global Offering	10%

Note: For details of the final allocation of shares to the Hong Kong Public Offering, investors can refer to www.eipo.com.hk/eIPOAllotment to perform a search by identification number or www.eipo.com.hk/eIPOAllotment for the full list of allottees.

INTERNATIONAL OFFERING

No. of placees	120
Subscription level	3.45 times
No. of Offer Shares initially available under the International Offering	7,199,250
No. of Offer Shares reallocated to the Hong Kong Public Offering	0
Final no. of Offer Shares under the International Offering	7,199,250
% of Offer Shares under the International Offering to the Global Offering	90%

The Directors confirm that, to the best of their knowledge, information and belief, (i) none of the Offer Shares subscribed by the placees and the public have been financed directly or indirectly by the Company, any of the Directors, supervisors, chief executive of the Company, controlling shareholders, substantial shareholders, existing shareholders of the Company or any of its subsidiaries or their respective close associates; and (ii) none of the placees and the public who have purchased the Offer Shares are accustomed to taking instructions from the Company, any of the Directors, supervisors, chief executive of the Company, controlling shareholders, substantial shareholders, existing shareholders of the Company or any of its subsidiaries or their respective close associates in relation to the acquisition, disposal, voting or other disposition of Shares registered in his/her/its name or otherwise held by him/her/it.

The placees in the International Offering include the following:

Allotees with Consent Obtained

<i>Investor</i>	<i>Number of Offer Shares allocated</i>	<i>% of total number of Offer Shares</i>	<i>% of total issued share capital after the Global Offering</i>	<i>Relationship</i>
<i>Allottees with consent under paragraph 1C(1) of Appendix F1 to the Listing Rules (“Placing Guidelines”) in relation to allocations to a connected client⁽¹⁾</i>				
Huatai Capital Investment Limited (“ HTCI ”)	31,350	0.39%	0.04%	HTCI and Huatai Financial Holdings (Hong Kong) Limited (“ Huatai ”) are group companies within the same group
<p><i>Notes:</i></p> <p>(1) For details of the consent under paragraph 1C(1) of the Placing Guidelines in relation to allocations to a connected client, please refer to the section headed “Others/Additional Information – Placing to a connected client with a prior consent under paragraph 1C(1) of the Placing Guidelines” in this announcement.</p>				

LOCK-UP UNDERTAKINGS

Controlling Shareholders(As Defined in the Prospectus)

<i>Name</i>	<i>Number of Shares held in the Company subject to lock-up undertakings upon listing^{Note (7)}</i>	<i>Number of H shares held in the Company subject to lock-up undertakings upon listing^{Note (7)}</i>	<i>% of total issued H Shares after the Global Offering subject to lock-up undertakings upon listing</i>	<i>% of shareholding in the Company subject to lock-up undertakings upon listing</i>	<i>Last day subject to the lock-up undertakings</i>
Dr. Song Ning ("Dr. Song") ^{Note (1), (2), (3), (4) and (5)}	24,293,507	24,293,507	27.33%	27.33%	March 30, 2027 ^{Note (6)}
Hangzhou Diagens Nuohui Investment Management Partnership Enterprise (Limited Partnership) (杭州德適諾輝投資管理合夥企業(有限合夥))("Diagens Nuohui") ^{Note (2)}	7,614,901	7,614,901	8.57%	8.57%	March 30, 2027 ^{Note (6)}
Hangzhou Diagens Nuoda Technology Management Partnership Enterprise (Limited Partnership) (杭州德適諾達科技管理合夥企業(有限合夥))("Diagens Nuoda") ^{Note (3)}	4,759,247	4,759,247	5.35%	5.35%	March 30, 2027 ^{Note (6)}
Hangzhou Deqian Technology Management Partnership Enterprise (Limited Partnership) (杭州德仟科技管理合夥企業(有限合夥))("Deqian Technology")	3,530,834	3,530,834	3.97%	3.97%	March 30, 2027 ^{Note (6)}
Hangzhou Diagens Nuoxin Investment Management Partnership Enterprise (Limited Partnership) (杭州德適諾鑫投資管理合夥企業(有限合夥))("Diagens Nuoxin")	1,903,668	1,903,668	2.14%	2.14%	March 30, 2027 ^{Note (6)}
Subtotal	42,102,157	42,102,157	47.37%	47.37%	

Notes:

- (1) Dr. Song beneficially holds 24,293,507 Shares.
- (2) Diagens Nuohui, being an ESOP Platform, is managed and controlled by its general partner, Dr. Song. Diagens Nuohui is owned as to approximately 61.35% by Hangzhou Defeng Acceleration Technology Management Partnership (Limited Partnership) (杭州德豐加速科技管理合夥企業(有限合夥)) (“**Defeng Acceleration**”) as its limited partner, which is in turn owned as to approximately 99.84% by Dr. Song as its general partner. Diagens Nuohui is owned as to approximately 36.61% by Hangzhou Defeng Origin Technology Management Partnership (Limited Partnership) (杭州德豐起源科技管理合夥企業(有限合夥)) (“**Defeng Origin**”) as its limited partner, which is in turn managed by Dr. Song as its general partner and not owned as to more than 30% by any of its limited partners. Diagens Nuohui is owned as to approximately 1.94% by Hangzhou Defeng Rise Technology Limited Partnership (杭州德豐升騰科技管理合夥企業(有限合夥)), which is in turn managed by Dr. Song as its general partner and not owned as to more than 30% by any of its limited partners.

As such, under the SFO, each of Dr. Song, Defeng Acceleration and Defeng Origin is deemed to be interested in the 7,614,901 Shares held by Diagens Nuohui.
- (3) Diagens Nuoda is managed by its general partner, Dr. Song. None of the limited partners (not including Dr. Song who is the general partner) of Diagens Nuoda owns more than 30% of limited partnership interests therein. As such, under the SFO, Dr. Song is deemed to be interested in the 4,759,247 Shares held by Diagens Nuoda.
- (4) Deqian Technology is managed by its general partner, Dr. Song. And Deqian Technology is owned as to approximately 99.90% by Hangzhou Dezhi Technology Management Partnership (Limited Partnership) (杭州德智科技管理合夥企業(有限合夥)) as the sole limited partner, which is in turn owned as to approximately 76.71% by Dr. Song as its general partner.

As such, under the SFO, each of Dr. Song and Hangzhou Dezhi Technology Management Partnership (Limited Partnership) is deemed to be interested in the 3,530,834 Shares held by Deqian Technology.
- (5) Diagens Nuoxin is managed by its general partner, Dr. Song. And Diagens Nuoxin is owned as to approximately 62.50% by Mr. GUO Jian (郭健) as its limited partner. None of other limited partners of Diagens Nuoxin owns more than 30% of partnership interests therein.

As such, under the SFO, each of Dr. Song and Mr. GUO Jian is deemed to be interested in the 1,903,668 Shares held by Diagens Nuoxin.
- (6) According to the PRC Company Law, all the Shares held by the existing Shareholders prior to the Global Offering are subject to a lock-up period of 12 months following the Listing Date.
- (7) Calculated based on the assumption that all 80,880,000 Unlisted Shares will be converted into H Shares upon listing.

Other Existing Shareholders (including the Pre-IPO Investors as defined in the “History, Development and Corporate Structure” section of the Prospectus)

<i>Name</i>	<i>Number of Shares held in the Company subject to lock-up undertakings upon listing^{Note (3)}</i>	<i>Number of H Shares held in the Company subject to lock-up undertakings upon listing^{Note (3)}</i>	<i>% of total issued H Shares after the Global Offering subject to lock-up undertakings upon listing</i>	<i>% of shareholding in the Company subject to lock-up undertakings upon listing</i>	<i>Last day subject to the lock-up undertakings</i>
Hangzhou Zicheng Investment Management Limited Partnership (Limited Partnership) (杭州紫城投資管理合夥企業(有限合夥)) ^{Note (1)}	2,539,107	2,539,107	2.86%	2.86%	30 March 2027 ^{Note (2)}
Hangzhou Zizhou Investment Management Limited Partnership (Limited Partnership) (杭州紫洲投資管理合夥企業(有限合夥)) ^{Note (1)}	4,694,039	4,694,039	5.28%	5.28%	30 March 2027 ^{Note (2)}
Hangzhou Zizheng Investment Management Limited partnership (Limited Partnership) (杭州紫正投資管理合夥企業(有限合夥)) ^{Note (1)}	1,546,877	1,546,877	1.74%	1.74%	30 March 2027 ^{Note (2)}
Ningbo Jiayuan Venture Capital Limited Partnership (Limited Partnership) (寧波嘉緣創業投資合夥企業(有限合夥)) ^{Note (1)}	3,498,695	3,498,695	3.94%	3.94%	30 March 2027 ^{Note (2)}

<i>Name</i>	<i>Number of Shares held in the Company subject to lock-up undertakings upon listing^{Note (3)}</i>	<i>Number of H Shares held in the Company subject to lock-up undertakings upon listing^{Note (3)}</i>	<i>% of total issued H Shares after the Global Offering subject to lock-up undertakings upon listing</i>	<i>% of shareholding in the Company subject to lock-up undertakings upon listing</i>	<i>Last day subject to the lock-up undertakings</i>
Guozhong Private Equity Investment Fund (Xi'an) Limited Partnership (Limited Partnership) (國中私募股權投資基金(西安)合夥企業(有限合夥)) ^{Note (1)}	2,959,964	2,959,964	3.33%	3.33%	30 March 2027 ^{Note (2)}
Hunan Xiangjiang Liyuan Jiankun Venture Capital Limited Partnership (Limited Partnership) (湖南湘江力遠健鯤創業投資合夥企業(有限合夥)) ^{Note (1)}	2,959,964	2,959,964	3.33%	3.33%	30 March 2027 ^{Note (2)}
Nanjing Huarui Ruichuang Venture Capital Center (Limited Partnership) (南京華睿睿創創業投資中心(有限合夥)) ^{Note (1)}	986,655	986,655	1.11%	1.11%	30 March 2027 ^{Note (2)}
Jiaxing Weixin No. 1 Equity Investment Limited Partnership (Limited Partnership) (嘉興惟馨壹號股權投資合夥企業(有限合夥)) ^{Note (1)}	986,655	986,655	1.11%	1.11%	30 March 2027 ^{Note (2)}
Qingdao Juancheng Equity Investment Limited Partnership (Limited Partnership) (青島雋誠股權投資合夥企業(有限合夥)) ^{Note (1)}	986,655	986,655	1.11%	1.11%	30 March 2027 ^{Note (2)}
Lishui Jingen Private Equity Limited Partnership (Limited Partnership) (麗水金巨股權投資合夥企業(有限合夥)) ^{Note (1)}	986,655	986,655	1.11%	1.11%	30 March 2027 ^{Note (2)}
Hangzhou Huayun Equity Investment Limited Partnership (Limited Partnership) (杭州花雲股權投資合夥企業(有限合夥)) ^{Note (1)}	197,330	197,330	0.22%	0.22%	30 March 2027 ^{Note (2)}

<i>Name</i>	<i>Number of Shares held in the Company subject to lock-up undertakings upon listing^{Note (3)}</i>	<i>Number of H Shares held in the Company subject to lock-up undertakings upon listing^{Note (3)}</i>	<i>% of total issued H Shares after the Global Offering subject to lock-up undertakings upon listing</i>	<i>% of shareholding in the Company subject to lock-up undertakings upon listing</i>	<i>Last day subject to the lock-up undertakings</i>
Hangzhou Yuxijin Equity Investment Limited Partnership (Limited Partnership) (杭州餘汐金股權投資合夥企業(有限合夥)) ^{Note (1)}	1,479,975	1,479,975	1.67%	1.67%	30 March 2027 ^{Note (2)}
Tianjin Binhai Yuanyi Jimao Private Equity Limited Partnership (Limited Partnership) (天津濱海遠翼吉茂股權投資合夥企業(有限合夥)) ^{Note (1)}	1,945,119	1,945,119	2.19%	2.19%	30 March 2027 ^{Note (2)}
Tianjin Yuanyi Yongxuan Enterprise Management Center (Limited Partnership) (天津遠翼永宣企業管理中心(有限合夥)) ^{Note (1)}	1,945,119	1,945,119	2.19%	2.19%	30 March 2027 ^{Note (2)}
Tianjin Yongqian Enterprise Management Center (Limited Partnership) (天津永乾企業管理中心(有限合夥)) ^{Note (1)}	194,512	194,512	0.22%	0.22%	30 March 2027 ^{Note (2)}
Hangzhou Hetu No. 6 Private Equity Limited Partnership (Limited Partnership) (杭州和途六號股權投資合夥企業(有限合夥)) ^{Note (1)}	4,491,905	4,491,905	5.05%	5.05%	30 March 2027 ^{Note (2)}
Hangzhou Yuhang Jingkai Private Equity Limited Partnership (Limited Partnership) (杭州餘杭經開股權投資基金合夥企業(有限合夥)) ^{Note (1)}	1,296,745	1,296,745	1.46%	1.46%	30 March 2027 ^{Note (2)}
Hunan Xiangjiang Liyuan Jianxiao Venture Capital Limited Partnership (Limited Partnership) (湖南湘江力遠健瀟創業投資合夥企業(有限合夥)) ^{Note (1)}	648,374	648,374	0.73%	0.73%	30 March 2027 ^{Note (2)}

<i>Name</i>	<i>Number of Shares held in the Company subject to lock-up undertakings upon listing^{Note (3)}</i>	<i>Number of H Shares held in the Company subject to lock-up undertakings upon listing^{Note (3)}</i>	<i>% of total issued H Shares after the Global Offering subject to lock-up undertakings upon listing</i>	<i>% of shareholding in the Company subject to lock-up undertakings upon listing</i>	<i>Last day subject to the lock-up undertakings</i>
Jiaxing Qingyulan No. 1 Venture Capital Limited Partnership (Limited Partnership) (嘉興青於藍壹號創業投資合夥企業(有限合夥)) ^{Note (1)}	383,419	383,419	0.43%	0.43%	30 March 2027 ^{Note (2)}
Hangzhou Hefu Private Equity Limited Partnership (Limited Partnership) (杭州和馥股權投資合夥企業(有限合夥)) ^{Note (1)}	2,154,451	2,154,451	2.42%	2.42%	30 March 2027 ^{Note (2)}
Hangzhou Huarui Ruiyin Venture Capital Partnership (Limited Partnership) (杭州華睿睿銀創業投資合夥企業(有限合夥)) ^{Note (1)}	947,814	947,814	1.07%	1.07%	30 March 2027 ^{Note (2)}
Zhejiang Hongshiliang Group Jigongjia Wine Co., Ltd. (浙江紅石樑集團濟公家酒坊有限公司) ^{Note (1)}	947,814	947,814	1.07%	1.07%	30 March 2027 ^{Note (2)}
Subtotal	38,777,843	38,777,843	43.64%	43.64%	
<i>Notes:</i> (1) Please refer to the section headed “History, Development and Corporate Structure — Principal Terms of the Pre-IPO Investments” in the Prospectus for details of the Pre-IPO Investors (2) According to the PRC Company Law, all the Shares held by the existing Shareholders prior to the Global Offering are subject to a lock-up period of 12 months following the Listing Date. (3) Calculated based on the assumption that all 80,880,000 Unlisted Shares will be converted into H Shares upon listing.					

PLACEE CONCENTRATION ANALYSIS

Places*	Number of H Shares allotted	Allotment as % of International Offering	Allotment as % of total Offer Shares	Number of Shares held upon Listing	% of total issued share capital upon Listing
Top 1	879,150	12.21%	10.99%	879,150	0.99%
Top 5	2,545,700	35.36%	31.82%	2,545,700	2.86%
Top 10	3,894,600	54.10%	48.69%	3,894,600	4.38%
Top 25	5,491,350	76.28%	68.65%	5,491,350	6.18%

Notes

* Ranking of placees is based on the number of H Shares allotted to the placees.

H SHAREHOLDERS CONCENTRATION ANALYSIS

H Shareholders*	Number of H Shares allotted	Allotment as % of International Offering	Allotment as % of total Offer Shares	Number of H Shares held upon Listing	% of total issued H Share capital upon Listing	Number of Shares held upon Listing
Top 1	0	0.00%	0.00%	42,102,157	47.37%	42,102,157
Top 5	0	0.00%	0.00%	65,143,308	73.29%	65,143,308
Top 10	0	0.00%	0.00%	78,170,270	87.95%	78,170,270
Top 25	4,093,500	56.86%	51.17%	84,778,988	95.39%	84,778,988

Notes

* Ranking of Shareholders is based on the number of Shares (of all classes) held by the Shareholder upon Listing

SHAREHOLDERS CONCENTRATION ANALYSIS

Shareholders*	Number of H Shares allotted	Allotment as % of International Offering	Allotment as % of total Offer Shares	Number of H Shares held upon Listing	Number of Shares held upon Listing	% of total issued share capital upon Listing
Top 1	0	0.00%	0.00%	42,102,157	42,102,157	47.37%
Top 5	0	0.00%	0.00%	65,143,308	65,143,308	73.29%
Top 10	0	0.00%	0.00%	78,170,270	78,170,270	87.95%
Top 25	4,093,500	56.86%	51.17%	84,778,988	84,778,988	95.39%

Notes

* Ranking of Shareholders is based on the number of Shares (of all classes) held by the Shareholder upon Listing

BASIS OF ALLOCATION UNDER THE HONG KONG PUBLIC OFFERING

Subject to the satisfaction of the conditions set out in the Prospectus, valid applications made by the public will be conditionally allocated on the basis set out below:

NO. OF SHARES APPLIED FOR	NO. OF VALID APPLICATIONS	BASIS OF ALLOTMENT / BALLOT POOL A	APPROXIMATE PERCENTAGE ALLOTTED OF THE TOTAL NO. OF SHARES APPLIED FOR
50	62,439	1,873 out of 62,439 to receive 50 Shares	3.00%
100	5,013	167 out of 5,013 to receive 50 Shares	1.67%
150	1,687	58 out of 1,687 to receive 50 Shares	1.15%
200	1,570	57 out of 1,570 to receive 50 Shares	0.91%
250	1,569	58 out of 1,569 to receive 50 Shares	0.74%
300	1,058	41 out of 1,058 to receive 50 Shares	0.65%
350	752	30 out of 752 to receive 50 Shares	0.57%
400	5,549	224 out of 5,549 to receive 50 Shares	0.50%
450	1,008	42 out of 1,008 to receive 50 Shares	0.46%
500	3,247	140 out of 3,247 to receive 50 Shares	0.43%
600	858	39 out of 858 to receive 50 Shares	0.38%
700	628	31 out of 628 to receive 50 Shares	0.35%
800	1,708	87 out of 1,708 to receive 50 Shares	0.32%
900	1,193	63 out of 1,193 to receive 50 Shares	0.29%
1,000	2,389	133 out of 2,389 to receive 50 Shares	0.28%
1,500	1,444	97 out of 1,444 to receive 50 Shares	0.22%
2,000	1,239	98 out of 1,239 to receive 50 Shares	0.20%
2,500	1,041	95 out of 1,041 to receive 50 Shares	0.18%
3,000	828	85 out of 828 to receive 50 Shares	0.17%
3,500	652	74 out of 652 to receive 50 Shares	0.16%
4,000	649	82 out of 649 to receive 50 Shares	0.16%
4,500	547	75 out of 547 to receive 50 Shares	0.15%
5,000	1,356	204 out of 1,356 to receive 50 Shares	0.15%
6,000	757	131 out of 757 to receive 50 Shares	0.14%
7,000	713	141 out of 713 to receive 50 Shares	0.14%
8,000	597	132 out of 597 to receive 50 Shares	0.14%
9,000	651	159 out of 651 to receive 50 Shares	0.14%
10,000	3,031	812 out of 3,031 to receive 50 Shares	0.13%
20,000	1,660	829 out of 1,660 to receive 50 Shares	0.12%
30,000	1,020	746 out of 1,020 to receive 50 Shares	0.12%
40,000	1,244	1,197 out of 1,244 to receive 50 Shares	0.12%
<u>108,097</u>		Total number of Pool A successful applicants: 8,000	

NO. OF SHARES APPLIED FOR	NO. OF VALID APPLICATIONS	BASIS OF ALLOTMENT / BALLOT POOL B	APPROXIMATE PERCENTAGE ALLOTTED OF THE TOTAL NO. OF SHARES APPLIED FOR
50,000	3,420	2,848 out of 3,420 to receive 50 Shares	0.08%
60,000	730	660 out of 730 to receive 50 Shares	0.08%
70,000	476	50 Shares	0.07%
		50 Shares plus 15 out of 301 to receive additional 50	
80,000	301	Shares	0.07%
		50 Shares plus 28 out of 227 to receive additional 50	
90,000	227	Shares	0.06%
		50 Shares plus 120 out of 614 to receive additional 50	
100,000	614	Shares	0.06%
		50 Shares plus 205 out of 369 to receive additional 50	
150,000	369	Shares	0.05%
200,000	194	100 Shares	0.05%
		100 Shares plus 30 out of 107 to receive additional 50	
250,000	107	Shares	0.05%
300,000	122	150 Shares	0.05%
		150 Shares plus 58 out of 360 to receive additional 50	
399,950	360	Shares	0.04%
	<u>6,920</u>	Total number of Pool B successful applicants: 6,278	

As of the date of this announcement, the relevant subscription monies previously deposited in the designated nominee accounts have been remitted back to the accounts of all HKSCC participants. Investors should contact their relevant brokers for any inquiries.

COMPLIANCE WITH LISTING RULES AND GUIDANCE

The Directors confirm that, except for the Listing Rules that consent has been obtained, the Company has complied with the Listing Rules and guidance materials in relation to the placing, allotment and listing of the Company's H Shares.

The Directors confirm that, to the best of their knowledge, the consideration paid by the placees or the public (as the case may be) directly or indirectly for each Offer Share subscribed for or purchased by them was the same as the Offer Price in addition to any brokerage, AFRC transaction levy, SFC transaction levy and Hong Kong Stock Exchange trading fee payable.

OTHERS/ADDITIONAL INFORMATION

Placing to a connected client with a prior consent under paragraph 1C(1) of the Placing Guidelines

The Company has applied to the Hong Kong Stock Exchange for, and the Hong Kong Stock Exchange has granted, a consent under paragraph 1C of the Placing Guidelines to permit the Company to allocate the Offer Shares in the International Offering to a connected client. The allocation of Offer Shares to such a connected client is in compliance with all the conditions under the consent granted by the Hong Kong Stock Exchange. Details of the placement to a connected client are set out below:

<i>No.</i>	<i>Connected Client</i>	<i>Connected Distributor</i>	<i>Relationship with the Connected Distributor</i>	<i>Basis of holding securities</i>	<i>Number of Offer Shares (rounded down to nearest whole board lots of 50 Shares) to be allocated to the connected client</i>	<i>Appropriate percentage of total number of Offer Shares</i>	<i>Approximate percentage of total Shares in issue immediately following the completion of Global Offering</i>
1.	Huatai Capital Investment Limited (“HTCI”) ⁽¹⁾	Huatai Financial Holdings (Hong Kong) Limited (“Huatai”)	HTCI and Huatai are group companies within the same group	Non-discretionary	31,350	0.39%	0.04%

Notes:

1. PRC investors are currently not permitted under applicable PRC laws to participate directly in initial public offerings (“IPOs”) in Hong Kong. However, PRC investors are permitted to invest in products issued by appropriate domestic securities firms licensed to undertake cross-border derivatives trading activities. In connection with such products, the licensed domestic securities firms, through their Hong Kong affiliates, may participate in Hong Kong IPOs either as placees or cornerstone investors (the “**Cross-border Derivatives Trading Regime**”).

Huatai Securities Co., Ltd. (“**Huatai Securities**”), the shares of which are listed on both the Shanghai Stock Exchange (stock code: 601688) and the Hong Kong Stock Exchange (stock code: 6886), is one of the domestic securities firms licensed to undertake cross-border derivatives trading activities. Huatai Securities entered into an ISDA agreement (the “**ISDA Agreement**”) with its indirectly wholly-owned subsidiary, HTCI, to set out the principal terms of any future total return swap between Huatai Securities and HTCI.

Huatai is the Sole Sponsor and one of the Overall Coordinators and Underwriters in connection with the Global Offering. Pursuant to an ISDA agreement entered into between Huatai Securities and HTCI, HTCI will hold the beneficial interest of the Offer Shares on a non-discretionary basis as the single underlying holding under a back-to-back total return swap (“**Huatai Back-to-back TRS**”) to be entered by HTCI in connection with a Client TRS (as defined below) placed by and fully funded (i.e. with no financing provided by HTCI) by Huatai Ultimate Clients (as defined below), by which, HTCI will, subject to customary fees and commissions, pass the full economic exposure of the Offer Shares ultimately to the Huatai Ultimate Clients, which in effect, HTCI will hold the beneficial interest of the Offer Shares on behalf of the Huatai Ultimate Clients.

HTCI and Huatai are both indirectly wholly-owned subsidiaries of Huatai Securities. Accordingly, HTCI is considered as a “connected client” of Huatai pursuant to paragraph 1B(7) of the Placing Guidelines.

Pursuant to the Cross-border Derivatives Trading Regime, the onshore investors (“**Huatai Ultimate Clients**”) cannot directly subscribe for the Offer Shares but may invest in derivative products issued by domestic securities firms licenced to undertake cross-border derivatives trading activities, such as Huatai Securities, with the Offer Shares as the underlying assets. Instead of directly subscribing for the Offer Shares, the Huatai Ultimate Clients, through their investment managers, will place a total return swap order (“**Client TRS**”) with Huatai Securities in connection with the Company’s IPO and Huatai Securities will place a Huatai Back-to-back TRS order to HTCI on the terms of the ISDA Agreement. In order to hedge its exposure under the Huatai Back-to-back TRS, HTCI participates in the Company’s IPO and subscribes the Offer Shares through placing order with Huatai during the International Offering.

To the best of HTCI’s knowledge and after making all reasonable enquiries, each of the Huatai Ultimate Clients is an independent third party of (i) the Company, the connected person and/or their respective associates thereof, and (ii) HTCI, Huatai and the companies which are members of the same group of HTCI.

The purpose of HTCI to subscribe for the Offer Shares is for hedging the Huatai Back-to-back TRS in connection with the Client TRS order placed by the Huatai Ultimate Clients. Pursuant to the terms of the contracts of the Huatai Back-to-back TRS and the Client TRS, during the tenor of the Huatai Back-to-back TRS and the Client TRS, subject to customary fees and commissions, all economic returns of the Offer Shares will be ultimately passed to the Huatai Ultimate Clients through the Huatai Back-to-back TRS and the Client TRS and all economic loss shall be ultimately borne by the Huatai Ultimate Clients. HTCI will not take any economic return or bear any economic loss in relation to the Offer Shares.

Investment in the Huatai Back-to-back TRS and the Client TRS is similar to the investment in a qualified domestic institutional investor fund (“**QDII**”) in the way that the Huatai Ultimate Clients would reap all the economic benefits of the underlying Offer Shares, except that a QDII fund would pass through the exchange rate exposure on both the notional value of the investment and the profit and loss of the investment. In contrast, the profit and loss of the Huatai Back-to-back TRS and the Client TRS factor into account the fluctuation in RMB exchange rate upon termination of the Client TRS by converting the profit and loss using the current exchange rate at the time of termination. As such, the Huatai Ultimate Clients would bear the exchange rate exposure of the profit and loss on settlement date.

The Huatai Ultimate Clients may exercise an early termination right to terminate the Client TRS at any time from the issue date of the Client TRS which should be on or after the date on which the Offer Shares are listed on the Hong Kong Stock Exchange at their own discretions. Upon the termination upon maturity or early termination of the Client TRS by the Huatai Ultimate Clients, HTCI will dispose the Offer Shares on the secondary market and the Huatai Ultimate Clients will receive a final settlement amount in cash in accordance with the terms and conditions of the Huatai Back-to-back TRS and the Client TRS which should have taken into account all the economic returns or economic loss in relation to the Offer Shares. If upon the maturity of the Client TRS, the Huatai Ultimate Clients intend to extend the investment period, subject to further agreement between Huatai Securities and the relevant Huatai Ultimate Clients, the term of the Client TRS could be extended by way of a new issuance or a tenor extension. Accordingly, Huatai Securities will extend the term of the Huatai Back-to-back TRS by way of a new issuance or a tenor extension.

It is proposed that HTCI will hold the legal title and the voting right of the Offer Shares by itself, and pass through the economic exposure to the Huatai Ultimate Clients, each being an onshore client who places a Client TRS order with Huatai Securities in connection with the IPO of the Company. HTCI will not exercise the voting right of the Offer Shares during the tenor of the Huatai Back-to-back TRS.

During the life of the Client TRS and Huatai Back-to-back TRS, HTCI may continue to hold the Offer Shares in its custodian account, or to hold some or all of the Offer Shares in a prime brokerage account for stock borrowing purposes, HTCI will lend out its holding of underlying Offer Shares in the form of stock borrowing loans consistent with market practice to lower its finance costs, provided that HTCI has the ability to call back the Offer Shares on loan at any time in order to satisfy its obligations under the Huatai Back-to-back TRS to ensure the economic interests are ultimately passed to the Huatai Ultimate Clients.

2. The details of the ultimate beneficial owners of Huatai Ultimate Clients are as follows:

- (1) Guangzhou Haizhu Digital Economy Industrial Investment Management Co., Limited (廣州市海珠數字經濟創業投資管理有限公司) (“**Guangzhou Haizhu**”) is limited liability company established in the PRC. As of the date hereof, the sole ultimate beneficial owner of Guangzhou Haizhu is Haizhu District Bureau of Science, Industry, Commerce and Information Technology of Guangzhou Municipality (廣州市海珠區科技工業商務和信息化局) (“**Haizhu District Bureau**”). Haizhu District Bureau is a government body under the Guangdong Provincial Government.
- (2) Shanghai Yongjin Investment Management Co., Ltd. (上海涌津投資管理有限公司) is a limited liability company established in the PRC. It acts as the fund manager of Yongjin Yongxin No.52 Private Securities Investment Fund (涌津涌鑫52號私募證券投資基金) (“**Yongxin No.52 Fund**”). As of the date hereof, Yongxin No.52 Fund has 14 limited partners and none of them holds 30% or more limited partnership interests.

DISCLAIMERS

*Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (the “**Hong Kong Stock Exchange**”) and Hong Kong Securities Clearing Company Limited (“**HKSCC**”) take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

*This announcement is not for release, publication, distribution, directly or indirectly, in or into the United States (including its territories and possessions, any state of the United States and the District of Columbia). This announcement does not constitute or form a part of any offer or solicitation to purchase or subscribe for securities in the United States. The securities mentioned herein have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the “**U.S. Securities Act**”). The securities may not be offered or sold in the United States except pursuant to an exemption from the registration requirements of the U.S. Securities Act and in compliance with any applicable state securities laws, or outside the United States unless in compliance with Regulation S under the U.S. Securities Act. There will be no public offer of securities in the United States.*

The Offer Shares are being offered and sold outside the United States in offshore transactions in reliance on Regulation S under the U.S. Securities Act.

This announcement is for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for securities. This announcement is not a prospectus. Potential investors should read the Prospectus dated March 20, 2026 issued by Hangzhou Diagens Biotechnology Co., Ltd. for detailed information about the Global Offering described below before deciding whether or not to invest in the Shares thereby being offered.

Potential investors of the Offer Shares should note that the Sponsor-overall Coordinator (for itself and on behalf of the Hong Kong Underwriters) shall be entitled to terminate their obligations under the Hong Kong Underwriting Agreement with immediate effect upon the occurrence of any of the events set out in the paragraph headed “Underwriting — Underwriting Arrangements and Expenses — Hong Kong Public Offering — Hong Kong Underwriting Agreement — Grounds for Termination” in the Prospectus at any time prior to 8:00 a.m. (Hong Kong time) on the Listing Date (which is currently expected to be on Monday, March 30, 2026).

PUBLIC FLOAT AND FREE FLOAT

Immediately following the completion of the Global Offering and the conversion of Unlisted Shares into H Shares, an aggregate of 46,777,043 H Shares, representing approximately 52.63% of the total issued share capital of the Company will be held in the public hands for the purpose of Rule 8.08 of the Listing Rules, which is higher than the prescribed percentage of H Shares required to be held in public hands of 15% with the expected market value at the time of listing over HK\$6,000,000,000 but not exceeding HK\$30,000,000,000 under the Rule 8.08(1), calculated based on the final Offer Price of HK\$99.0 per H Share, thereby satisfying Rule 19A.13A(1) of the Listing Rules.

The Directors confirm that, immediately following the completion of the Global Offering, (i) no placee will, individually, be placed more than 10% of the enlarged issued share capital of the Company immediately after the Global Offering; (ii) there will not be any new substantial Shareholder immediately after the Global Offering; (iii) the three largest public Shareholders do not hold more than 50% of the Shares held in the public hands at the time of the Listing in compliance with Rules 8.08(3) and 8.24 of the Listing Rules; and (iv) there will be at least 300 Shareholders at the time of the Listing in compliance with Rule 8.08(2) of the Listing Rules.

COMMENCEMENT OF DEALINGS

The H Share certificates will only become valid evidence of title at 8:00 a.m. on Monday, March 30, 2026 (Hong Kong time), provided that the Global Offering has become unconditional and the right of termination described in the paragraph headed “Underwriting — Underwriting Arrangements and Expenses — Hong Kong Public Offering — Grounds for Termination” in the Prospectus has not been exercised. Investors who trade the H Shares on the basis of publicly available allocation details prior to the receipt of H Share certificates or prior to the H Share certificates becoming valid evidence of title do so entirely at their own risk.

Assuming that the Global Offering becomes unconditional at or before 8:00 a.m. Monday, March 30, 2026 (Hong Kong time), it is expected that dealings in the H Shares on the Hong Kong Stock Exchange will commence at 9:00 a.m. on Monday, March 30, 2026 (Hong Kong time). The H Shares will be traded in board lots of 50 H Shares each, and the stock code of the H Shares will be 2526.

By order of our Board
Hangzhou Diagens Biotechnology Co., Ltd.
Song Ning
Chairman of the Board and Executive Director

Hong Kong, March 27, 2026

As of the date of this announcement, the Board comprises: (i) Dr. Song Ning and Mr. Weng Chih-Hsin (alias Robin Weng) as executive Directors; (ii) Dr. Xu Chen, Dr. Wu Lingqian and Mr. Yang Zehao as non-executive Directors; and (iii) Mr. Cha Yang (alias Stanley Cha), Ms. Zhang Jing and Mr. Wang Kaifeng as independent non-executive Directors.